所有图片(1)
别名:
替格瑞洛, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-二氟苯基)环丙基]氨基}-5(丙硫基)-3H-[1,2,3]-三唑并[4,5-d]吡啶基-3-yl]-5-(2-羟基乙氧基)环戊烷-1,2-二醇, (1 S ,2 S ,3 R ,5 S )-3-[7-{[(1 R ,2 S )-2-（3,4-二氟苯基）环丙基] 氨基 }-5-（丙基砜基）-3 H - [1,2,3] 三唑 [4,5- d 嘧啶-3-基]-5-（2-羟乙氧基）-1,2-环戊二醇
经验公式（希尔记法）:
C23H28F2N6O4S
推荐产品
![4-[4-(三氟甲基)苯基]-2,4-二氧代丁酸乙酯 97%](/deepweb/assets/sigmaaldrich/product/structures/220/172/2faec313-5b7c-4814-8642-7ece1977126a/640/2faec313-5b7c-4814-8642-7ece1977126a.png)
检测方案
≥98% (HPLC)
形式
powder
旋光性
[α]/D -55 to -65°, c = 0.2 in methanol
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
−20°C
SMILES字符串
CCCSC1=NC(N[C@@]2([H])[C@@](C3=CC=C(F)C(F)=C3)([H])C2)=C4C(N([C@@]5([H])[C@H](O)[C@H](O)[C@@H](OCCO)C5)N=N4)=N1
InChI
1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
InChI key
OEKWJQXRCDYSHL-FNOIDJSQSA-N
基因信息
human ... P2RY12(64805)
正在寻找类似产品? 访问 产品对比指南
一般描述
替格瑞洛(AZD6140)是一种环戊基三唑嘧啶。
生化/生理作用
替格瑞洛是一种抗血栓形成抗血小板药物，直接和可逆地竞争性抑制腺嘌呤受体P2Y12受体发挥作用。可用于治疗急性冠状动脉综合征患者。也可改善内皮功能。替格瑞洛可抑制人红细胞摄取腺苷，促进人红细胞释放腺苷三磷酸(ATP)。
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Athanasios Moulias et al.
Journal of cardiovascular pharmacology and therapeutics, 24(1), 11-17 (2018-07-12)
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门